Cronos Group Inc vs Teradyne, Inc. — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Teradyne, Inc. trades at $402.42 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 52.8× Cronos Group Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Teradyne, Inc. for 37 Days on average.
| CRON | TER | |
|---|---|---|
Market Cap | $1.18B | $62.34B |
Volume | 968,037 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $3.55 | $483.84 |
52-Week Low | $2.30 | $132.05 |
Typical Hold Time | 22 Days | 37 Days |
Enterprise Value | $387.62M | $62.08B |
Dividend Yield | — | 0.13% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
Teradyne (TER) trades at $403.88, down 1.92% on the day, yet maintains a bullish technical stance with strong analyst support. The company exhibits robust profitability with a 25.77% net income margin and 36.66% ROE, supported by consecutive earnings beats. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, positioning TER to capitalize on semiconductor and data center demand growth.
The outlook is positive, driven by strategic product launches and strong earnings momentum, with a consensus price target of $461.50 implying ~14% upside. Key risks include execution challenges in a competitive semiconductor equipment market and sensitivity to cyclical industry demand, which could pressure valuation multiples if growth slows.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →